Johnson & Johnson (J&J) has received approval from the US Food and Drug Administration (FDA) for its TECNIS PureSee extended depth of focus (EDOF) intraocular lens (IOL), designed for use in cataract surgery.
The company stated that 97% of patients reported no very bothersome visual disturbances with this lens.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The TECNIS PureSee IOL is expected to become available for US patients later this year.
It addresses both cataract-related vision loss and presbyopia, which affects near vision as eyes age. Around 94 million people aged 50 and above currently have moderate-to-severe distance vision impairment or blindness that may be treated by lens replacement surgery.
TECNIS PureSee IOL is said to be the first and only FDA-approved EDOF IOL in the US without a warning on loss of contrast sensitivity.
Based on the TECNIS platform, the lens combines advanced optics with proprietary materials to extend depth of focus and address presbyopia.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt provides intermediate vision with some near vision and also reduces reliance on glasses after surgery.
The approval adds to J&J’s surgical vision portfolio, which includes other lenses such as TECNIS Odyssey IOL (a full visual range IOL) and TECNIS Eyhance IOL (a monofocal lens designed to slightly extend depth of focus).
The TECNIS PureSee IOL has global approval and has already been implanted in nearly half a million eyes following cataract surgery.
Johnson & Johnson Vision company group chairman Peter Menziuso said: “The approval of the TECNIS PureSee IOL gives surgeons an important new lens option, reflecting our deep commitment to innovation that delivers high patient satisfaction and supports vision solutions tailored to individual lifestyle needs.
“Cataract surgery is often a once-in-a-lifetime opportunity for patients to restore and enhance their vision. With the addition of TECNIS PureSee IOL to our portfolio, we can help even more patients regain not just sight, but the quality, range, and visual performance they expect from a Johnson & Johnson product.”
In November 2025, J&J MedTech reported one-year outcomes from the DISRUPT BTK II trial of the Shockwave Peripheral intravascular lithotripsy system to treat calcified lesions below the knee (BTK) in individuals with peripheral artery disease.
